TNB-383B is a laboratory-created antibody that facilitates the interaction between immune cells and cancer cells, resulting in a more targeted immune response. This antibody specifically targets the B-cell maturation antigen found in myeloma cells and the CD3 surface receptor present in T-cells, acting as a link between the two. The initial trial of TNB-383B in humans, conducted in collaboration with AbbVie, aims to assess the safety and tolerability of the compound, as well as various pharmacological characteristics including its peak concentration in the bloodstream and its half-life (the duration for a dose to decrease to half of its initial amount).
Cell Line Name:
Host Cell Line:
ELISA | FACS
>95% by SDS-PAGE and SEC-HPLC
<0.5 EU/mg as determined by the LAL method
20mM sodium citrate,150mM NaCl, pH5.5
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
SDS-PAGE | SEC-HPLC | ELISA | FACS
1.A Phase 1 First-in-Human Study of Tnb-383B, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in Patients with Relapsed/Refractory Multiple Myeloma
2.A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma
F2 Building, Yizhuang Biomedical Park, No. 88, Kechuang Six Street, Beijing. P.R. China. 101111.